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Abstract 
BACKGROUND: Most experts accept the use of curettage, phenol, and cement as the best treatment to prevent recurrence 
of giant-cell tumors. The purpose of this investigation was to analyze the effect of cement as a filling material and com-
pare it with bone graft and the effect of high-speed burr in local recurrence of giant cell tumor after curettage. 
METHODS: We retrospectively reviewed 168 consecutive patients diagnosed with giant cell tumor at the three most 
common sites (distal femur, proximal tibia, and distal radius) to determine the pattern of local tumor recurrence. Only 
patients who had intralesional excision of primary tumor by curettage without a surgical adjuvant were included.  
RESULTS: A total of 168 patients with primary giant cell tumor were treated with curettage. The female to male ratio 
was 1.4: 1 and the mean age was 34 years (range: 17-68 years). The minimum follow-up was 24 months and the median 
follow up was 75 months. The knee region was involved in 135 (80.4%) patients. There were 10 (5.9%), 130 (77.4%) 
and 28 (16.7%) patients in Campanacci grade I, II and III, respectively. Tumor surgery was supplemented with high 
speed burring in 88 (52.4%), bone cement in 82 (48.8%) and bone grafting, either autograft or allograft in 86 (51.2%) 
patients. The recurrence rates were 18.2% and 37.5% for curettage with or without high speed burring, respectively. For 
46 (27%) recurrent lesions treated by curettage, the recurrence rate was 35%. The nature of the filling material used did 
not show any significant impact on the outcome of recurrence rate. 
CONCLUSIONS: Despite the high rates of recurrence after treatment of giant-cell tumor with curettage, the results of the 
present study suggested that the high-speed burr is effective in reducing the rate of recurrence. The risk of local recur-
rence after curettage with a high-speed burr and reconstruction with bone graft is similar to that observed after using 
cement. It is likely that the adequacy of the removal of the tumor rather than the use of adjuvant modalities is what de-
termines the risk of recurrence. 
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iant cell tumor of bones is an unusual 
neoplasm that accounts for 4% of all 
primary tumors of bone.1 Usually, the 
age of patients ranges from 20 to 55 years, and 
the peak age incidence is in the third decade of 
life, with slight female predominance (1.2:1). It 
is a locally aggressive tumor, which involves 
 
the ends of long bones in skeletally mature in-
dividuals in more than 80% of cases, and 75% 
of them occur around the knee joint.1 The tu-
mor on occasion invades the articular space, 
also involving the ligaments and the synovial 
membrane. Extension to an adjacent bone 
through the joint occurs in 5 per cent of the  
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tumors. Less frequently, giant cell tumors oc-
cur in the vertebrae (2-5%) and in the sacrum 
(10%).1 Giant cell tumor is characterized by its 
typical location in the epiphysis of long bone. 
Rarely, when it occurs in teenagers with an 
open physis, the metaphyseal area may be in-
volved first.2,3 This tumor is well known for its 
potential to recur after treatment such as curet-
tage or incomplete resection, which leaves mi-
croscopic residuals.4,5 Recurrence can develop 
in the bone or soft tissues and although both 
reflect relapse of disease, the sequelae of recur-
rence can vary as a function of the site and ex-
tent. Historically, the rate of local recurrence 
after curettage and bone grafting has been re-
ported to range between 25% and 50%.6-10 This 
has led surgeons to enhance their surgical pro-
cedure with adjuvants such as liquid nitro-
gen,11,12 acrylic cement,13,14 phenol,6,15,16 hydro-
gen peroxide,17 locally delivered chemother-
apy,18 or radiation therapy. The latter has been 
associated with malignant transformation in 
the past,6,19,20 but the risk of this complication 
recently has been challenged and may be dif-
ferent with modern radiotherapy modali-
ties.21,22 Wide resection is associated with much 
better local control, but it often impairs limb 
function because it implies the sacrifice of a 
significant segment of bone.8,23,24 Adjuvant liq-
uid nitrogen has been reported to provide the 
best local control but its use has not gained 
popularity because handling the product is dif-
ficult and pathologic fractures have been fre-
quent.11,12 Although acrylic cement initially 
seemed to enhance local control,21,25 this has 
been challenged.6,23 Comparably low local re-
currence rates have been reported using mod-
ern surgical techniques without the addition of 
adjuvant.26 Compared with other filler material 
such as autograft or allograft bone, cement is 
easy and inexpensive to use, provides immedi-
ate stability allowing early weight-bearing may 
avoid the necessity of internal fixation, and al-
lows for early detection of recurrence as a lytic 
defect at the bone-cement interface.27,28 Cement 
also can be used when a fracture is present.29 
The risk of joint degeneration after cementa-
tion seems to be minimal,30-32 although some 
authors prefer to interpose bone chips between 
cartilage or subchondral area and cement in an 
attempt to prevent joint degeneration.4 The 
purpose of this investigation was to analyze 
the effect of cement and high speed burring in 
recurrence rate of giant cell tumor after curet-
tage. The primary hypothesis was that the use 
of any one or a combination of them would not 
provide better local control. 
Methods 
We retrospectively identified the records of 205 
patients from the database maintained by the 
Orthopedic Oncology Service of our hospital 
between 1975 and 2004. We included all pa-
tients diagnosed with primary giant cell tumor 
arising in the distal femur, proximal tibia, and 
distal radius with a minimum follow-up of 2 
years after treatment. Patients with multifocal 
lesions involving one or more of these sites 
were not included. Only patients who had in-
tralesional excision of tumor by curettage were 
included and any patient who originally had 
been treated elsewhere was excluded from this 
study. Base on these criteria, 168 cases of 205 
patients were entered in the study. Seventy-
five tumors were in the distal femur, 53 were 
in the proximal tibia, and 40 were in the distal 
radius. Medical records and radiographs were 
reviewed for all patients for whom a local re-
currence developed. Anatomic site of the tu-
mor, first surgical procedure, and timing of the 
local recurrence were determined. The pathol-
ogy of the primary and locally recurrent tumor 
was confirmed in all cases. Radiographs were 
assessed for adequacy and thoroughness of 
initial treatment and site of recurrence (bone or 
soft tissue), and location within the bone (sub-
chondral or metaphyseal bone). Local recur-
rences were analyzed in eight groups: patients 
who were treated by simple curettage and 
bone graft (group A), simple curettage and 
cementing (group B), curettage with high-
speed burring and bone graft (group C), curet-
tage with high-speed burring and cementing 
(group D), cementing with or without burring 
(group E), bone graft with or without burring 
(group F). Burring with cement or bone graft 
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(group G), simple curettage with cement or 
bone graft (group H). There was not significant 
statistical difference among these groups for 
sex, age, location and grading of tumor. Analy-
sis of the data was focused on the effect of ce-
ment and high-speed burr in local recurrence 
of tumors. The data analyzed with Epi-info 
software (version 3.4.1). 
Results 
The average age of the 168 patients was 34 
years (range of 17-68 years). There were 99 fe-
males and 69 males (female to male ratio was 
1.43:1). Age and sex distribution among cases 
with GCT are shown in figure 1. Campanacci 
grading was as follows: grade 1, ten patients, 
grade 2, 130 patients and grade 3, 28 patients 
(Figure 2). Seventy-five tumors were in the dis-
tal femur, 53 were in the proximal tibia, and 40 
were in the distal radius. The distal femur and 
the proximal tibia accounted for 76% of all lo-
cations. The follow up ranged from 24 to 192 
months (median, 74 months). The average fol-
low-up did not differ between patients who 
had a recurrence and patients who did not 
have a recurrence (P = 0.08). After curettage, a 
high-speed burr was used in 88 patients 
(group E). The cavity was filled with bone 
graft in 86 patients (Figure 3) (autograft only in 
18 patients and allograft in 68 patients) and 
cement in 82 patients (group F) (Figure 4). 
Forty-six patients of the 168 had developed a 
local recurrence (27.4%). Forty-two patients 
had the first recurrence in bone and four pa-
tients developed a soft tissue recurrence as 
their first recurrence. Twenty tumors recurred 
in the distal femur, sixteen recurred in the 
proximal tibia, and ten recurred in the distal 
radius. Recurrence in proximal tibia (30.2%) 
was more than that in distal parts of femur 
(26.7%) and radius (25%), but there was not a 
statistical difference between the primary sites 
of the tumor and the recurrence sites. The av-
erage recurrence occurred at 30 months (range, 
6–54 months) and there was no statistical dif-
ference between the times of recurrence in dif-
ferent locations (p value = 0.125). The local re-
currence rate in the groups was shown in the 
table 1. The group that received curettage was 
analyzed to determine whether patients who 
received cement had recurrences less often 
than patients who received grafts but no statis-
tical difference in the recurrence rate was 
found (p value = 0.117). Statistical difference in 
the recurrence rate was found between pa-
tients who received high-speed burring curet-
tage and who had simple curettage (p value = 
0.0487). Patients presenting with a local recur-
rence had a significantly higher risk of having 
another recurrence with a rate of 35% (p < 0.05) 
if they got curettage again; 32 of 46 patients 
with local recurrence were operated with cu-
rettage again and recurrence rate of them was 
35%. Others were operated with resection and 
allograft or oncologic prosthesis and recur-
rence rate of them was only 7%. No significant 
statistical effect on local recurrence rate was 
identified for gender, tumor location and 
Campanacci grading for the groups. 
 
Figure 1. Age and sex distribution among 
cases with GCT. 
 
Figure 2. Distribution of cases according to 
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(a)                                     (b)                                (c)                                   (d) 
 
(e)                                       (f) 
 
Figure 3. A 17 year old male with left distal tibia giant cell tumor; AP x-ray (a), Lateral x-ray (b) 
CT-scan (c), MRI (d), AP and lateral x-ray 2 years after curettage with high speed burr and bone 
graft without recurrence (e, f). 
 
(a) (b)  (c) (d) 
 
Figure 4. A 51 year old female with right proximal tibia giant cell tumor; AP x-ray (a), Lateral x-
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Table 1. Local recurrences were analyzed in 
eight groups. 

































We included only the patients whom had cu-
rettage with bone graft or cement and we ex-
cluded patients whose initial surgery were other 
kinds like wide excision and allograft or on-
cologic prosthesis. Then we did not analyze the 
first surgical procedure type versus recurrence 
except those that were explained. We explained 
that no significant statistical effect on local re-
currence rate could be identified for gender, 
tumor location and Campanacci grading for the 
groups. The histology types were not consid-
ered in this study because the new classification 
don’t accept any histologic grading for giant 
cell tumor as the last one that divided it into 
high and low grades. In the most pathologic 
reports of our patients, the histology grading 
was not reported. 
Discussion 
The adequacy of the tumor removal is critical 
to the successful management of GCT. Treat-
ment-related factors including intraoperative 
techniques to minimize the risk of local tumor 
recurrence in the bone and soft tissue are criti-
cal determinants of local tumor control. Tech-
nical aspects such as sufficient exposure, isola-
tion of the tumor, careful manipulation of the 
tumor to avoid contamination of the soft tis-
sues, thoroughness of the curettage, intra-
cavitary burring, addition of surgical adju-
vants, and sufficient osseous reconstruction are 
contributory factors that affect local tumor re-
currence and metastasis. Acrylic cement ini-
tially was reported to have an adjuvant role in 
the treatment of giant cell tumor of bone.6,13 
Proposed mechanisms involved either the tox-
icity of the acrylic monomer or thermal necro-
sis induced by cement polymerization.33
O’Donnel et al25 challenged this idea when 
they reported a series of patients with giant 
cell tumors treated with cement compared 
with other filling materials and found no dif-
ference in local recurrence. With respect to cu-
rettage and bone cement, the reported rate of 
local recurrence by O’Donnell et al using curet-
tage and bone cement was 33.3% that de-
creased to 16.6% when mechanical burr was 
used; so they recommended using the burr at 
the end of all procedures. In addition, when 
the lesion reached the subchondral bone in 
weight bearing areas they put a layer of bone 
cement first under the subchondral plate to 
support it and then fill the rest of the cavity 
either by bone cement or bone graft. In our 
study, the overall recurrence rate was 36.2% 
after curettage without high-speed burring. 
The recurrence rate when high speed burring 
has been used was 19.3%. There was no sig-
nificant difference between cement and bone 
graft in local recurrence but there was signifi-
cant difference between curettage with high-
speed burr and without it. The use of the me-
chanical burr easily can extend the curettage 
and allow for a more controlled debridement 
of the cavity walls to minimize damage to un-
involved tissues while it may reduce the resid-
ual disease observed. The current report sug-
gests an improvement in the local control rate 
of these tumors with modern curettage tech-
niques. In this study we compared the role of 
filling material and high-speed burr but 
O’Donnel’s study focused only on the filling 
material. The recurrence rate when cementing 
and burring was done to gether was less than 
that in bone graft without burring but the dif-
ference was not significant. The recurrence 
rates in our study were a little more than that 
in O’Donnel’s study. As reported previously, 
no correlation could be found between Cam-
panacci radiographic classification and the risk 
of recurrence13,34 that have been shown in our 
study. The successful treatment of local recur-
rence after intralesional excision by curettage is 
site-of-recurrence specific and treatment spe-
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cific. The soft tissue recurrences were observed 
less frequently and were readily addressed 
with no adverse sequelae. In our series, soft 
tissue recurrences without bone recurrences 
were observed in only four cases.  
Conclusions 
Despite the high rates of recurrence after treat-
ment of giant-cell tumor with curettage, the  
 
results of the present study suggested that the 
high-speed burr is effective in reducing the 
rate of recurrence. The risk of local recurrence 
after curettage with a high-speed burr and re-
construction with bone graft was similar to 
that observed after use of cement. It is likely 
that the adequacy of the removal of the tumor 
rather than the use of adjuvant modalities is 
what determines the risk of recurrence. 
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